Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$453M |
| 2 |
CELG
Celgene Corp
CELG
|
+$391M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$389M |
| 4 |
GE Aerospace
GE
|
+$378M |
| 5 |
Johnson & Johnson
JNJ
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$307M |
| 2 |
Costco
COST
|
+$279M |
| 3 |
Lowe's Companies
LOW
|
+$273M |
| 4 |
Microsoft
MSFT
|
+$230M |
| 5 |
Chevron
CVX
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.07% |
| 2 | Technology | 14.35% |
| 3 | Financials | 11.23% |
| 4 | Consumer Discretionary | 9.93% |
| 5 | Real Estate | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
INVX
2826
Innovex International
INVX
$2.15B
| $758K | ﹤0.01% |
15,800
-117,600
| -88% | -$5.11M |
|
|
SCU
2827
DELISTED
Sculptor Capital Management, Inc. Class A Common Stock
SCU
| $758K | ﹤0.01% |
33,014
+19,335
| +141% | +$344K |
|
2828
Skyworks Solutions
SWKS
$10.5B
| $755K | ﹤0.01% |
9,774
-606,564
| -98% | -$48.1M |
|
|
MRIN
2829
DELISTED
Marin Software
MRIN
| $754K | ﹤0.01% |
51,113
+1,967
| +4% | +$45K |
|
|
QHC
2830
DELISTED
Quorum Health Corporation
QHC
| $754K | ﹤0.01% |
542,288
+372,909
| +220% | +$612K |
|
2831
Team
TISI
$101M
| $749K | ﹤0.01% |
+4,892
| New | +$789K |
|
|
SHOE
2832
Shoe Station Group
SHOE
$420M
| $748K | ﹤0.01% |
54,200
-1,400
| -3% | -$21.8K |
|
|
DVAX
2833
DELISTED
Dynavax Technologies
DVAX
| $747K | ﹤0.01% |
+187,251
| New | +$1.09M |
|
|
FBMS
2834
DELISTED
The First Bancshares, Inc.
FBMS
| $743K | ﹤0.01% |
24,500
+6,000
| +32% | +$183K |
|
2835
Columbia Banking Systems
COLB
$9.12B
| $742K | ﹤0.01% |
20,506
-59,100
| -74% | -$2.09M |
|
2836
MeiraGTx Holdings
MGTX
$1.17B
| $742K | ﹤0.01% |
+27,600
| New | +$570K |
|
2837
Yatra Online
YTRA
$56M
| $742K | ﹤0.01% |
198,300
+12,700
| +7% | +$55.9K |
|
2838
Under Armour Class C
UA
$2.25B
| $737K | ﹤0.01% |
+33,207
| New | +$691K |
|
2839
Cimpress
CMPR
$2.4B
| $736K | ﹤0.01% |
8,100
-19,409
| -71% | -$1.75M |
|
2840
Astec Industries
ASTE
$994M
| $734K | ﹤0.01% |
+22,537
| New | +$756K |
|
|
GFED
2841
DELISTED
Guaranty Federal Bancshares In
GFED
| $730K | ﹤0.01% |
31,400
+1,000
| +3% | +$23K |
|
|
NBSE
2842
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| $729K | ﹤0.01% |
10,691
+2,271
| +27% | +$129K |
|
|
HK
2843
DELISTED
Halcon Resources Corporation
HK
| $726K | ﹤0.01% |
4,106,956
+2,796,756
| +213% | +$2.04M |
|
2844
Union Bankshares
UNB
$120M
| $725K | ﹤0.01% |
19,600
+2,500
| +15% | +$94K |
|
|
CATC
2845
DELISTED
CAMBRIDGE BANCORP
CATC
| $725K | ﹤0.01% |
8,900
+2,200
| +33% | +$181K |
|
2846
AXT Inc
AXTI
$5.07B
| $723K | ﹤0.01% |
182,467
+160,011
| +713% | +$749K |
|
2847
iShares Russell 2000 Growth ETF
IWO
$15.1B
| $723K | ﹤0.01% |
3,600
+600
| +20% | +$119K |
|
|
CONN
2848
DELISTED
Conn's Inc.
CONN
| $723K | ﹤0.01% |
40,568
-73,200
| -64% | -$1.61M |
|
|
BSCM
2849
DELISTED
Invesco BulletShares 2022 Corporate Bond ETF
BSCM
| $723K | ﹤0.01% |
33,794
-47,306
| -58% | -$1M |
|
2850
Enpro
NPO
$7.12B
| $721K | ﹤0.01% |
+11,300
| New | +$738K |
|
Similar funds
Jim Simons's Q2 2019 Portfolio in Review
As of Q2 2019, Jim Simons held 3,913 positions worth $114B, up 3.3% from $110B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Jim Simons's Q2 2019 filing shows 495 new, 1,847 increased, 1,145 reduced and 397 closed positions. Its largest new stake was Apple: 9,290,160 shares worth $460M. The largest sale was UnitedHealth, an estimated $307M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 17% a quarter earlier, followed by Technology and Financials.
- Jim Simons's largest Q2 2019 buy was Apple: 9,290,160 shares worth $460M.
- Jim Simons added most to Celgene Corp in Q2 2019, an estimated $391M increase.
- Jim Simons's biggest Q2 2019 reduction was Microsoft, cutting an estimated $230M.
- Jim Simons fully exited UnitedHealth in Q2 2019, selling an estimated $307M.
- Jim Simons's ten largest holdings make up 9.1% of its $114B portfolio in Q2 2019.
- Jim Simons opened 495 new positions and closed 397 in Q2 2019.
- Jim Simons's portfolio value rose 3.3% quarter-over-quarter to $114B.
Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.